Skip to main content

Multiple Postdoc and Technician Positions Available at Baylor College of Medicine

 

Multiple postdoc and technician positions are available in Dr. Jin Wang’s group in the Department of Pharmacology and Chemical Biology at Baylor College of Medicine (BCM).

BCM is located in the world largest medical center and has access to enormous biomedical resources. The research in the Wang lab is highly interdisciplinary and translational. The Wang lab has both chemistry and biology operations. For chemistry work, we have 17 chemical fume hoods, 4 ISCO combiflash chromatography systems, Agilent analytical LC-MS, Agilent preparative HPLC with auto-purification, and Genevac high throughput solvent evaporation, along with convenient access to 600 and 800 MHz NMR. For biology work, we have common equipment for biochemistry, molecular and cell biology, including tissue culture hoods, RT-PCR, plate reader, and imaging plate reader, and perform animal work to evaluate the efficacy of the experimental therapeutics developed in the group. In addition, we recently acquired a state-of-the-art Thermo Orbitrap Fusion Lumos Tribrid Mass Spec with UPLC and NanoLC to perform metabolomics and proteomics studies and a high-performance computing (HPC) unit with 2X Tesla V100 GPUs for omics data analysis, molecular docking, and molecular dynamics studies. The lab is well-funded with multiple NIH grants, and government and industry-sponsored research contracts. These recruitments are mainly sponsored by a recent major drug discovery support from NIH.

The major research directions include small molecule drug discovery, and probe and sensor development for biological applications. Our small molecule drug design program includes structured based drug design (in collaboration with Dr. Hui Zheng), targeting unstructured steroid receptor coactivators and hormone receptors (PNAS 2016, in in collaboration with Dr. Bert O’Malley), anti-aging drug development (in collaboration with Dr. Meng Wang), and recent initiative in proteolysis targeting chimeras (PROTACs, Nat Comm 2020, in collaboration with Dr. Michael Wang). Our probe development effort leads to the most widely used (>100 labs worldwide) reversible-reaction based fluorescent probe for glutathione quantification in living cells (Nat Comm 2017). Along with our colleagues, we founded biotech companies to commercialize some of these research efforts.

The goal of these recruitments is to further expand our efforts in small molecule drug discovery and streamline bioactivity and ADMET testing. The candidates will gain experience not only for cutting-edge research but also drug discovery process in a biotech-like environment. The candidates will join a dynamic interdisciplinary group and should be willing and able to communicate with people from different backgrounds, including chemistry, engineering, and biology.


4X Postdoc Positions in Organic Chemistry or Medicinal Chemistry

Qualifications and Responsibilities

  1. The candidate should have a Ph.D. degree in organic chemistry or medicinal chemistry, or related fields.
  2. The candidate should have at least one first authored publication in internationally recognized journals, such as JACS, Angew, JOC, OL, and JMC etc.
  3. The candidate should be motivated, independent, creative, and energetic, and willing to step out of his/her comfort zone to learn new techniques and knowledge in biology.

Compensation and Benefits

Standard benefits for postdoc

Job Type: Full-time

Salary: following NIH postdoc salary scale and depending on qualifications; minimum $52,704 per year

Application

Applicants should fill out the online application form and email a cover letter, CV including names of three references and research summary in one PDF file to bcmwanglab2011@gmail.com DO NOT email Dr. Wang directly.


2X Research Technician Positions in Biology

Qualifications and Responsibilities

  1. The candidate should have a B.S. or M.S. degree in biology or related fields with minimum GPA 3.0. Prior research experience is not required.
  2. The candidate should be motivated, and willing to learn new techniques and knowledge in biology.
  3. The candidate will work under the direction of a senior member in the group.
  4. We prefer the candidate to be able to stay in the group for at least 2-3 years.

Compensation and Benefits

Standard benefits for faculty and staff

Job Type: Full-time

Salary: minimum $36,000 per year depending on qualifications

Application

Applicants should fill out the online application form and email a cover letter, resume including names of three references and transcripts in one PDF file to bcmwanglab2011@gmail.com DO NOT email Dr. Wang directly.

 1X Research Technician Position in Chemistry

Qualifications and Responsibilities

  1. The candidate should have a B.S. or M.S. degree in chemistry or related fields with minimum GPA 3.0. Prior research experience is not required.
  2. The candidate should be motivated, and willing to learn new techniques and knowledge in chemistry.
  3. The candidate will work under the direction of a senior member in the group.
  4. We prefer the candidate to be able to stay in the group for at least 2-3 years.

Compensation and Benefits

Standard benefits for faculty and staff

Job Type: Full-time

Salary: minimum $36,000 per year depending on qualifications

Application

Applicants should fill out the online application form and email a cover letter, resume including names of three references and transcripts in one PDF file to bcmwanglab2011@gmail.com DO NOT email Dr. Wang directly.

 

Comments

Post a Comment

Popular posts from this blog

Photoswitchable azopyrazoles Flipping the Switches of Ion Channels

Abnormally activated Ca 2+ channels are related to many human diseases, including Stormorken Syndrome, which makes Ca 2+ release-activated Ca 2+ (CRAC) channel a very promising therapeutic target. Several small molecule therapeutics targeting CRAC channels have been developed, including the GSKs series and Synta 66 . Those compounds have relatively high specificity. Meanwhile, a controllable system that can be activated with a switch can probably serve as a convenient tool for further related research.    Photoswitchable chemistry has been applied to a lot of bioactive targets such as ion channels, receptors enzymes and nucleic acids. Recently, the Li group developed CRAC channel inhibitors that can be turned ‘on’ and ‘off’ by UV-light exposure. Scheme 1 . C onverting CRAC channel inhibitors, GSKs , into photoswitchable derivatives, piCRACs . Starting from the well-established GSK-based CRAC inhibitor ( Scheme 1 ), the authors developed a series of nitrosaniline
1 comment
Read more

Proteosome Inhibition Taps Into RNA Splicing

Multiple myeloma (MM) is a malignancy of white blood cells called plasma cells that reside mainly in the bone marrow and is the second most common blood cancer. With increased understanding of biology, the current use of immunomodulatory (IM) drugs and proteasome inhibitors (PI) have taken over the therapeutic landscape for MM. The combination of bortezomib (PI) with lenalidomiede (IM) and dexamethasone is commonly the initial treatment of choice. Early intervention seems to provide a good outcome, but unfortunately, many patients eventually relapse. A major goal in MM treatment is to increase the efficacy of proteasome inhibitors and prevent relapse. To investigate this, Huang et al. used unbiased mass spectrometry-based phosphoproteomics to identify potential vulnerabilities after treatment with the PI carfilzomib and discovered that splicing related proteins had significant changes in phosphorylation that is undetectable upon examination of RNA and protein abundance. Treatment w
Post a Comment
Read more

One Fluorine Atom Fixes Poor KRAS Inhibitors

KRAS  is the most frequently mutated oncogene in human cancer. In the past few decades, the KRAS oncoprotein had always been deemed as an “undruggable target” due to lack of binding surface and tightly binding to its substrate GTP. In 2013, the Shokat group identified that the mutant cysteine KRAS G12C creates a new allosteric pocket “switch-II pocket” which can be exploited to design covalent inhibitors. KRAS G12C accounts for more than 50% of the incidences of KRAS mutations, involving in many cancers, such as non-small cell lung cancer (NSCLC), colorectal adenocarcinomas and pancreatic cancer. KARS G12C has been an attractive target for drug discovery and development in both academia and industry. MRTX849 is a potent, orally available covalent inhibitor of KRAS G12C developed by Mirati Therapeutics and currently undergoing Phase I/II clinical trials. Recently, a paper published in Journal of Medicinal Chemistry reported the design and optimization of MRTX849 . The medi
Post a Comment
Read more